AMERICAN ORIENTAL BIOENGINEERING RATED 'BUY/4'
American Oriental Bioengineering has been rated 'Buy/4'
in an initiating Institutional report by Investrend Research analyst Kipley Lytel,
CFA, and assigned a target valuation of $6. The full report is at http://www.investrendresearch.com.
In it the analyst also stated: The rating is predicated on the price gap between
AOB's current stock price and the implied company intrinsic value, along with:(1)
AOB's 10+ year seasoned history recently marked by visible operational execution;
(2) 81% revenue and 85% net income year-over-year comparable period increases
for the nine-month period ended Sept. 30, 2005 (9mo2005), respectively.